Palonosetron


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Nausea and vomiting associated w/ cancer chemotherapy 500 mcg 1 hr before therapy. IV Nausea and vomiting associated w/ cancer chemotherapy 250 mcg over 30 sec approx 30 min before therapy. Prophylaxis of postoperative nausea and vomiting 75 mcg over 10 sec before induction of anaesthesia.
Special Precautions
Patient w/ history of constipation, intestinal obstruction, history or risk of QT interval prolongation, electrolyte abnormalities. Childn. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, somnolence or fatigue, if affected, do not drive or operate machinery. Monitoring Parameters Monitor for signs and symptoms of serotonin syndrome.
Adverse Reactions
Significant: QT prolongation, bradycardia, hypersensitivity reactions (e.g. anaphylaxis). Nervous: Headache, dizziness, somnolence, fatigue, weakness, anxiety, vertigo, flu-like symptoms, insomnia, paresthesia. CV: Nonsustained tachycardia, hypotension, HTN, MI, hot flush. GI: Constipation, diarrhoea, abdominal pain, dyspepsia, dry mouth, hiccups, flatulence, anorexia. Hepatic: Increased serum ALT/AST, bilirubin. Genitourinary: Urinary retention. Endocrine: Hyperkalaemia, electrolyte fluctuations, hyperglycaemia, metabolic acidosis, glycosuria. Musculoskeletal: Arthralgia. Ophthalmologic: Amblyopia. Otic: Tinnitus. Dermatologic: Pruritus, rash, allergic dermatitis. Others: Inj site reaction.
Potentially Fatal: Rarely, serotonin syndrome (e.g. altered mental status, autonomic instability, neuromuscular symptoms).
Drug Interactions
Decreased therapeutic effect of tramadol.
ATC Classification
A04AA05 - palonosetron ; Belongs to the class of serotonin (5HT3) antagonists. Used for the prevention of nausea and vomiting.
Disclaimer: This information is independently developed by CIMS based on palonosetron from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in